Laekna Inc. Submits Investigational New Drug Application for LAE103 to the U.S. FDA for Treatment of Sarcopenic Obesity and Muscle-Related Disease

Reuters

Jun 30

Laekna Inc. Submits Investigational New Drug Application for LAE103 to the U.S. FDA for Treatment of Sarcopenic Obesity and Muscle-Related Disease

Laekna Inc. has voluntarily announced the submission of an Investigational New Drug $(IND.AU)$ application to the U.S. Food and Drug Administration (FDA) for their internally discovered monoclonal antibody, LAE103. This precision therapy is being developed to treat sarcopenic obesity and muscle-related diseases. As part of their ongoing regulatory review, Laekna plans to evaluate the efficacy and safety of monoclonal antibodies targeting ActRIIA and ActRIIB in humans. It is important to note that LAE103 is still in development, and its successful commercialization is not guaranteed. The company's shareholders and potential investors are advised to exercise caution.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Laekna Inc. published the original content used to generate this news brief on June 30, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2547035421"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2547035421\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2547035421?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-30 08:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2547035421","market":"nz","top_or_hot":-1,"title":"Laekna Inc. Submits Investigational New Drug Application for LAE103 to the U.S. FDA for Treatment of Sarcopenic Obesity and Muscle-Related Disease","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Laekna Inc. Submits Investigational New Drug Application for LAE103 to the U.S. FDA for Treatment of Sarcopenic Obesity and Muscle-Related Disease\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Laekna Inc. has voluntarily announced the submission of an Investigational New Drug <a href=\"https://laohu8.com/S/IND.AU\">$(IND.AU)$</a> application to the U.S. Food and Drug Administration (FDA) for their internally discovered monoclonal antibody, LAE103. This precision therapy is being developed to treat sarcopenic obesity and muscle-related diseases. As part of their ongoing regulatory review, Laekna plans to evaluate the efficacy and safety of monoclonal antibodies targeting ActRIIA and ActRIIB in humans. It is important to note that LAE103 is still in development, and its successful commercialization is not guaranteed. The company's shareholders and potential investors are advised to exercise caution.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Laekna Inc. published the original content used to generate this news brief on June 30, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Laekna Inc. Submits Investigational New Drug Application for LAE103 to the U.S. FDA for Treatment of Sarcopenic Obesity and Muscle-Related Disease</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLaekna Inc. Submits Investigational New Drug Application for LAE103 to the U.S. FDA for Treatment of Sarcopenic Obesity and Muscle-Related Disease\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-30 08:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Laekna Inc. Submits Investigational New Drug Application for LAE103 to the U.S. FDA for Treatment of Sarcopenic Obesity and Muscle-Related Disease\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Laekna Inc. has voluntarily announced the submission of an Investigational New Drug <a href=\"https://laohu8.com/S/IND.AU\">$(IND.AU)$</a> application to the U.S. Food and Drug Administration (FDA) for their internally discovered monoclonal antibody, LAE103. This precision therapy is being developed to treat sarcopenic obesity and muscle-related diseases. As part of their ongoing regulatory review, Laekna plans to evaluate the efficacy and safety of monoclonal antibodies targeting ActRIIA and ActRIIB in humans. It is important to note that LAE103 is still in development, and its successful commercialization is not guaranteed. The company's shareholders and potential investors are advised to exercise caution.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Laekna Inc. published the original content used to generate this news brief on June 30, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02105","symbol_name":"来凯医药-B","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250630:nNDLv9DMj:1","article_id":"2547035421","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2547035421","pubTimestamp":1751242495,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Laekna Inc. Submits Investigational New Drug Application for LAE103 to the U.S. FDA for Treatment of Sarcopenic Obesity and Muscle-Related Disease. Laekna Inc. has voluntarily announced the submission of an Investigational New Drug  application to the U.S. Food and Drug Administration  for their internally discovered monoclonal antibody, LAE103. This precision therapy is being developed to treat sarcopenic obesity and muscle-related diseases. As part of their ongoing regulatory review, Laekna plans to evaluate the efficacy and safety of monoclonal antibodies targeting ActRIIA and ActRIIB in humans. It is important to note that LAE103 is still in development, and its successful commercialization is not guaranteed. The company's shareholders and potential investors are advised to exercise caution.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02105":"来凯医药-B","BK1161":"生物科技"},"translate_title":"Laekna Inc.向美国FDA提交LAE103的研究性新药申请，用于治疗肌肉减少性肥胖和肌肉相关疾病","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02105":0.9},"content_text":"Laekna Inc. Submits Investigational New Drug Application for LAE103 to the U.S. FDA for Treatment of Sarcopenic Obesity and Muscle-Related Disease\n    \n\n        Laekna Inc. has voluntarily announced the submission of an Investigational New Drug $(IND.AU)$ application to the U.S. Food and Drug Administration (FDA) for their internally discovered monoclonal antibody, LAE103. This precision therapy is being developed to treat sarcopenic obesity and muscle-related diseases. As part of their ongoing regulatory review, Laekna plans to evaluate the efficacy and safety of monoclonal antibodies targeting ActRIIA and ActRIIB in humans. It is important to note that LAE103 is still in development, and its successful commercialization is not guaranteed. The company's shareholders and potential investors are advised to exercise caution.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Laekna Inc. published the original content used to generate this news brief on June 30, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}